APO Research
Talk to an analyst

APO RESEARCH · REPORT

Viral Conjunctivitis Pipeline Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Viral Conjunctivitis Pipeline Drugs Market Outlook and Growth Opportunities 2026

21 December 2025192 pages

Choose your research edition.

Industry ResearchViral Conjunctivitis Pipeline Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Conjunctivitis Pipeline Drugs Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Viral Conjunctivitis Pipeline Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Conjunctivitis Pipeline Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Viral Conjunctivitis Pipeline Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Viral Conjunctivitis Pipeline Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Viral Conjunctivitis Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Viral Conjunctivitis Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Viral Conjunctivitis Pipeline Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Viral Conjunctivitis Pipeline Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Viral Conjunctivitis Pipeline Drugs market include Takeda, Novartis AG, Panoptes Pharma GES.M.B.H., NovaBay Pharmaceuticals Inc., NicOx S.A., NanoViricides Inc., Allergan Plc and Adenovir Pharma AB, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Viral Conjunctivitis Pipeline Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Viral Conjunctivitis Pipeline Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Viral Conjunctivitis Pipeline Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Viral Conjunctivitis Pipeline Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Viral Conjunctivitis Pipeline Drugs Segment by Company

Takeda

Novartis AG

Panoptes Pharma GES.M.B.H.

NovaBay Pharmaceuticals Inc.

NicOx S.A.

NanoViricides Inc.

Allergan Plc

Adenovir Pharma AB

Viral Conjunctivitis Pipeline Drugs Segment by Type

Acute Follicular Conjunctivitis Pipeline Drugs

Subacute Or Chronic Conjunctivitis Pipeline Drugs

Viral Conjunctivitis Pipeline Drugs Segment by Application

Hospitals

Clinics

Others

Viral Conjunctivitis Pipeline Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Viral Conjunctivitis Pipeline Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Viral Conjunctivitis Pipeline Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Viral Conjunctivitis Pipeline Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Viral Conjunctivitis Pipeline Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Conjunctivitis Pipeline Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Conjunctivitis Pipeline Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Conjunctivitis Pipeline Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Viral Conjunctivitis Pipeline Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Viral Conjunctivitis Pipeline Drugs industry.

Chapter 3: Detailed analysis of Viral Conjunctivitis Pipeline Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Viral Conjunctivitis Pipeline Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Viral Conjunctivitis Pipeline Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Viral Conjunctivitis Pipeline Drugs Industry Trends Table 2. Viral Conjunctivitis Pipeline Drugs Industry Drivers Table 3. Viral Conjunctivitis Pipeline Drugs Industry Opportunities and Challenges Table 4. Viral Conjunctivitis Pipeline Drugs Industry Restraints Table 5. Global Viral Conjunctivitis Pipeline Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Viral Conjunctivitis Pipeline Drugs Revenue Share by Company (2021-2026) Table 7. Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Company (tons) & (2021-2026) Table 8. Global Viral Conjunctivitis Pipeline Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Viral Conjunctivitis Pipeline Drugs Average Price (US$/ton) of Company (2021-2026) Table 10. Global Viral Conjunctivitis Pipeline Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Viral Conjunctivitis Pipeline Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Viral Conjunctivitis Pipeline Drugs Company, Product Type & Application Table 13. Global Viral Conjunctivitis Pipeline Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Viral Conjunctivitis Pipeline Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Acute Follicular Conjunctivitis Pipeline Drugs Table 18. Significant Companies of Subacute Or Chronic Conjunctivitis Pipeline Drugs Table 19. Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (tons) Table 20. Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Type (2021-2026) & (tons) Table 21. Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Type (2027-2032) & (tons) Table 22. Global Viral Conjunctivitis Pipeline Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Viral Conjunctivitis Pipeline Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Viral Conjunctivitis Pipeline Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Viral Conjunctivitis Pipeline Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Viral Conjunctivitis Pipeline Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type (2021-2026) Table 28. Global Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Table 30. Significant Companies of Clinics Table 31. Significant Companies of Others Table 32. Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (tons) Table 33. Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Application (2021-2026) & (tons) Table 34. Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Application (2027-2032) & (tons) Table 35. Global Viral Conjunctivitis Pipeline Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Viral Conjunctivitis Pipeline Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Viral Conjunctivitis Pipeline Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Viral Conjunctivitis Pipeline Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Viral Conjunctivitis Pipeline Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application (2021-2026) Table 41. Global Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application (2027-2032) Table 42. Global Viral Conjunctivitis Pipeline Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Table 43. Global Viral Conjunctivitis Pipeline Drugs Sales by Region (2021-2026) & (tons) Table 44. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Region (2021-2026) Table 45. Global Viral Conjunctivitis Pipeline Drugs Sales by Region (2027-2032) & (tons) Table 46. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Region (2027-2032) Table 47. Global Viral Conjunctivitis Pipeline Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Viral Conjunctivitis Pipeline Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Viral Conjunctivitis Pipeline Drugs Sales Value Share by Region (2021-2026) Table 50. Global Viral Conjunctivitis Pipeline Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Viral Conjunctivitis Pipeline Drugs Sales Value Share by Region (2027-2032) Table 52. Global Viral Conjunctivitis Pipeline Drugs Market Average Price (US$/ton) by Region (2021-2026) Table 53. Global Viral Conjunctivitis Pipeline Drugs Market Average Price (US$/ton) by Region (2027-2032) Table 54. Global Viral Conjunctivitis Pipeline Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Table 55. Global Viral Conjunctivitis Pipeline Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Viral Conjunctivitis Pipeline Drugs Sales by Country (2021-2026) & (tons) Table 57. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Country (2021-2026) Table 58. Global Viral Conjunctivitis Pipeline Drugs Sales by Country (2027-2032) & (tons) Table 59. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Country (2027-2032) Table 60. Global Viral Conjunctivitis Pipeline Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Viral Conjunctivitis Pipeline Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Viral Conjunctivitis Pipeline Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Viral Conjunctivitis Pipeline Drugs Sales Value Market Share by Country (2027-2032) Table 64. Takeda Company Information Table 65. Takeda Business Overview Table 66. Takeda Viral Conjunctivitis Pipeline Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 67. Takeda Viral Conjunctivitis Pipeline Drugs Product Portfolio Table 68. Takeda Recent Development Table 69. Novartis AG Company Information Table 70. Novartis AG Business Overview Table 71. Novartis AG Viral Conjunctivitis Pipeline Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 72. Novartis AG Viral Conjunctivitis Pipeline Drugs Product Portfolio Table 73. Novartis AG Recent Development Table 74. Panoptes Pharma GES.M.B.H. Company Information Table 75. Panoptes Pharma GES.M.B.H. Business Overview Table 76. Panoptes Pharma GES.M.B.H. Viral Conjunctivitis Pipeline Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 77. Panoptes Pharma GES.M.B.H. Viral Conjunctivitis Pipeline Drugs Product Portfolio Table 78. Panoptes Pharma GES.M.B.H. Recent Development Table 79. NovaBay Pharmaceuticals Inc. Company Information Table 80. NovaBay Pharmaceuticals Inc. Business Overview Table 81. NovaBay Pharmaceuticals Inc. Viral Conjunctivitis Pipeline Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 82. NovaBay Pharmaceuticals Inc. Viral Conjunctivitis Pipeline Drugs Product Portfolio Table 83. NovaBay Pharmaceuticals Inc. Recent Development Table 84. NicOx S.A. Company Information Table 85. NicOx S.A. Business Overview Table 86. NicOx S.A. Viral Conjunctivitis Pipeline Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 87. NicOx S.A. Viral Conjunctivitis Pipeline Drugs Product Portfolio Table 88. NicOx S.A. Recent Development Table 89. NanoViricides Inc. Company Information Table 90. NanoViricides Inc. Business Overview Table 91. NanoViricides Inc. Viral Conjunctivitis Pipeline Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 92. NanoViricides Inc. Viral Conjunctivitis Pipeline Drugs Product Portfolio Table 93. NanoViricides Inc. Recent Development Table 94. Allergan Plc Company Information Table 95. Allergan Plc Business Overview Table 96. Allergan Plc Viral Conjunctivitis Pipeline Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 97. Allergan Plc Viral Conjunctivitis Pipeline Drugs Product Portfolio Table 98. Allergan Plc Recent Development Table 99. Adenovir Pharma AB Company Information Table 100. Adenovir Pharma AB Business Overview Table 101. Adenovir Pharma AB Viral Conjunctivitis Pipeline Drugs Sales (tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 102. Adenovir Pharma AB Viral Conjunctivitis Pipeline Drugs Product Portfolio Table 103. Adenovir Pharma AB Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Viral Conjunctivitis Pipeline Drugs Distributors List Table 107. Viral Conjunctivitis Pipeline Drugs Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Viral Conjunctivitis Pipeline Drugs Product Image Figure 2. Global Viral Conjunctivitis Pipeline Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Viral Conjunctivitis Pipeline Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Viral Conjunctivitis Pipeline Drugs Sales (2021-2032) & (tons) Figure 5. Global Viral Conjunctivitis Pipeline Drugs Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Viral Conjunctivitis Pipeline Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Acute Follicular Conjunctivitis Pipeline Drugs Image Figure 10. Subacute Or Chronic Conjunctivitis Pipeline Drugs Image Figure 11. Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (tons) Figure 12. Global Viral Conjunctivitis Pipeline Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Viral Conjunctivitis Pipeline Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Viral Conjunctivitis Pipeline Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Viral Conjunctivitis Pipeline Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Clinics Image Figure 19. Others Image Figure 20. Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (tons) Figure 21. Global Viral Conjunctivitis Pipeline Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Viral Conjunctivitis Pipeline Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Viral Conjunctivitis Pipeline Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Viral Conjunctivitis Pipeline Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Viral Conjunctivitis Pipeline Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Figure 27. Global Viral Conjunctivitis Pipeline Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Viral Conjunctivitis Pipeline Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Viral Conjunctivitis Pipeline Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Viral Conjunctivitis Pipeline Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Viral Conjunctivitis Pipeline Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Viral Conjunctivitis Pipeline Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Viral Conjunctivitis Pipeline Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Viral Conjunctivitis Pipeline Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Viral Conjunctivitis Pipeline Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Viral Conjunctivitis Pipeline Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Viral Conjunctivitis Pipeline Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Viral Conjunctivitis Pipeline Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Viral Conjunctivitis Pipeline Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Viral Conjunctivitis Pipeline Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Viral Conjunctivitis Pipeline Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Acute Follicular Conjunctivitis Pipeline Drugs
  • Subacute Or Chronic Conjunctivitis Pipeline Drugs
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Takeda
  • Novartis AG
  • Panoptes Pharma GES.M.B.H.
  • NovaBay Pharmaceuticals Inc.
  • NicOx S.A.
  • NanoViricides Inc.
  • Allergan Plc
  • Adenovir Pharma AB

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Viral Conjunctivitis Pipeline Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Viral Conjunctivitis Pipeline Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Viral Conjunctivitis Pipeline Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Viral Conjunctivitis Pipeline Drugs Market Dynamics
  1. 2.1 Viral Conjunctivitis Pipeline Drugs Industry Trends
  2. 2.2 Viral Conjunctivitis Pipeline Drugs Industry Drivers
  3. 2.3 Viral Conjunctivitis Pipeline Drugs Industry Opportunities and Challenges
  4. 2.4 Viral Conjunctivitis Pipeline Drugs Industry Restraints
3 Viral Conjunctivitis Pipeline Drugs Market by Company
  1. 3.1 Global Viral Conjunctivitis Pipeline Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Viral Conjunctivitis Pipeline Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Viral Conjunctivitis Pipeline Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Viral Conjunctivitis Pipeline Drugs Company Ranking (2024-2026)
  6. 3.6 Global Viral Conjunctivitis Pipeline Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Viral Conjunctivitis Pipeline Drugs Company Product Type and Application
  8. 3.8 Global Viral Conjunctivitis Pipeline Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Viral Conjunctivitis Pipeline Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Viral Conjunctivitis Pipeline Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Viral Conjunctivitis Pipeline Drugs Market by Type
  1. 4.1 Viral Conjunctivitis Pipeline Drugs Type Introduction
  2. 4.1.1 Acute Follicular Conjunctivitis Pipeline Drugs
  3. 4.1.2 Subacute Or Chronic Conjunctivitis Pipeline Drugs
  4. 4.2 Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Type
  5. 4.2.1 Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Viral Conjunctivitis Pipeline Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Type
  9. 4.3.1 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type (2021-2032)
5 Viral Conjunctivitis Pipeline Drugs Market by Application
  1. 5.1 Viral Conjunctivitis Pipeline Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Application
  6. 5.2.1 Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Viral Conjunctivitis Pipeline Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Viral Conjunctivitis Pipeline Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Application
  10. 5.3.1 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application (2021-2032)
6 Viral Conjunctivitis Pipeline Drugs Regional Sales and Value Analysis
  1. 6.1 Global Viral Conjunctivitis Pipeline Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Viral Conjunctivitis Pipeline Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Viral Conjunctivitis Pipeline Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Viral Conjunctivitis Pipeline Drugs Sales by Region (2027-2032)
  5. 6.3 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Viral Conjunctivitis Pipeline Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Viral Conjunctivitis Pipeline Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Viral Conjunctivitis Pipeline Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Viral Conjunctivitis Pipeline Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Viral Conjunctivitis Pipeline Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Viral Conjunctivitis Pipeline Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Viral Conjunctivitis Pipeline Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Viral Conjunctivitis Pipeline Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Viral Conjunctivitis Pipeline Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Viral Conjunctivitis Pipeline Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Viral Conjunctivitis Pipeline Drugs Sales Value Share by Country, 2025 VS 2032
7 Viral Conjunctivitis Pipeline Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Viral Conjunctivitis Pipeline Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Viral Conjunctivitis Pipeline Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Viral Conjunctivitis Pipeline Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Viral Conjunctivitis Pipeline Drugs Sales by Country (2027-2032)
  6. 7.4 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Viral Conjunctivitis Pipeline Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Viral Conjunctivitis Pipeline Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Viral Conjunctivitis Pipeline Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Viral Conjunctivitis Pipeline Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Viral Conjunctivitis Pipeline Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Viral Conjunctivitis Pipeline Drugs Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Viral Conjunctivitis Pipeline Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Viral Conjunctivitis Pipeline Drugs Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Panoptes Pharma GES.M.B.H.
  14. 8.3.1 Panoptes Pharma GES.M.B.H. Company Information
  15. 8.3.2 Panoptes Pharma GES.M.B.H. Business Overview
  16. 8.3.3 Panoptes Pharma GES.M.B.H. Viral Conjunctivitis Pipeline Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Panoptes Pharma GES.M.B.H. Viral Conjunctivitis Pipeline Drugs Product Portfolio
  18. 8.3.5 Panoptes Pharma GES.M.B.H. Recent Developments
  19. 8.4 NovaBay Pharmaceuticals Inc.
  20. 8.4.1 NovaBay Pharmaceuticals Inc. Company Information
  21. 8.4.2 NovaBay Pharmaceuticals Inc. Business Overview
  22. 8.4.3 NovaBay Pharmaceuticals Inc. Viral Conjunctivitis Pipeline Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 NovaBay Pharmaceuticals Inc. Viral Conjunctivitis Pipeline Drugs Product Portfolio
  24. 8.4.5 NovaBay Pharmaceuticals Inc. Recent Developments
  25. 8.5 NicOx S.A.
  26. 8.5.1 NicOx S.A. Company Information
  27. 8.5.2 NicOx S.A. Business Overview
  28. 8.5.3 NicOx S.A. Viral Conjunctivitis Pipeline Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 NicOx S.A. Viral Conjunctivitis Pipeline Drugs Product Portfolio
  30. 8.5.5 NicOx S.A. Recent Developments
  31. 8.6 NanoViricides Inc.
  32. 8.6.1 NanoViricides Inc. Company Information
  33. 8.6.2 NanoViricides Inc. Business Overview
  34. 8.6.3 NanoViricides Inc. Viral Conjunctivitis Pipeline Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 NanoViricides Inc. Viral Conjunctivitis Pipeline Drugs Product Portfolio
  36. 8.6.5 NanoViricides Inc. Recent Developments
  37. 8.7 Allergan Plc
  38. 8.7.1 Allergan Plc Company Information
  39. 8.7.2 Allergan Plc Business Overview
  40. 8.7.3 Allergan Plc Viral Conjunctivitis Pipeline Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Allergan Plc Viral Conjunctivitis Pipeline Drugs Product Portfolio
  42. 8.7.5 Allergan Plc Recent Developments
  43. 8.8 Adenovir Pharma AB
  44. 8.8.1 Adenovir Pharma AB Company Information
  45. 8.8.2 Adenovir Pharma AB Business Overview
  46. 8.8.3 Adenovir Pharma AB Viral Conjunctivitis Pipeline Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Adenovir Pharma AB Viral Conjunctivitis Pipeline Drugs Product Portfolio
  48. 8.8.5 Adenovir Pharma AB Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Viral Conjunctivitis Pipeline Drugs Value Chain Analysis
  2. 9.1.1 Viral Conjunctivitis Pipeline Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Viral Conjunctivitis Pipeline Drugs Sales Mode & Process
  6. 9.2 Viral Conjunctivitis Pipeline Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Viral Conjunctivitis Pipeline Drugs Distributors
  9. 9.2.3 Viral Conjunctivitis Pipeline Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst